SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX), announced today that it has finalized an aggressive growth strategy to pursue available opportunities within the biotech arena. The strategy, discussed by Dr. Robert F. Ryan, CEO of Nuvilex, is designed to capitalize on management expertise and existing Nuvilex technology, will combine ongoing research and product development, and will include licensing agreements and the acquisition of targeted companies within the industry.
